HDAC2 has been implicated in the malignant phenotype of hepatocellular carcinoma via LAPTM4B activation and in cisplatin resistance in triple-negative breast cancer by modulating m6A-mediated DNA damage repair [56, 57]. This evidence concerns the gene LAPTM4B and hepatocellular carcinoma.